推荐产品
product name
MOR/CPR, 96042333
生物源
human lung
增長模式
Aggregates in suspension
染色體組型
Not specified
形態學
Not specified
產品
Not specified
受體
Not specified
技術
cell culture | mammalian: suitable
相關疾病
cancer
運輸包裝
dry ice
儲存溫度
−196°C
細胞系來源
Human lung adenocarcinoma, drug-resistant
細胞系描述
MOR/CPR has been developed by growing the parent line, MOR, in increasing concentrations of cisplatin. The cells are cross-resistant to melphalan but show little or no cross-resistance to other platinum compounds. Cisplatin accumulation has been found to be reduced compared to the parent line.
應用
Analysis of acquired drug resistance
培養基
RPMI 1640 + 2mM Glutamine + 1μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).
例行更新培養
Split subconfluent cultures (70-80%) 1:2 to 1:4 seeding at 2-4 x 10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. It is recommended to culture the cells without drug after resuscitation until the first passage. These cells produce a
其他說明
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门